Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $1.9 million.

  • Bolt Biotherapeutics' Current Deferred Revenue fell 314.56% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 314.56%. This contributed to the annual value of $3.0 million for FY2024, which is 3698.32% up from last year.
  • As of Q3 2025, Bolt Biotherapeutics' Current Deferred Revenue stood at $1.9 million, which was down 314.56% from $2.5 million recorded in Q2 2025.
  • Bolt Biotherapeutics' 5-year Current Deferred Revenue high stood at $5.2 million for Q3 2021, and its period low was $1.5 million during Q1 2021.
  • In the last 5 years, Bolt Biotherapeutics' Current Deferred Revenue had a median value of $2.5 million in 2024 and averaged $2.7 million.
  • In the last 5 years, Bolt Biotherapeutics' Current Deferred Revenue skyrocketed by 12956.06% in 2022 and then crashed by 5359.63% in 2023.
  • Over the past 5 years, Bolt Biotherapeutics' Current Deferred Revenue (Quarter) stood at $2.9 million in 2021, then plummeted by 30.53% to $2.0 million in 2022, then rose by 10.44% to $2.2 million in 2023, then soared by 36.98% to $3.0 million in 2024, then crashed by 36.68% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $2.5 million for Q2 2025, and $3.1 million during Q1 2025.